Literature DB >> 19654062

Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine.

Ioanna Skountzou1, Maria del Pilar Martin, Baozhong Wang, Ling Ye, Dimitrios Koutsonanos, Will Weldon, Joshy Jacob, Richard W Compans.   

Abstract

Bacterial flagellins are potent inducers of innate immune responses in the mouse lung because they bind to TLR5 expressed on the apical surfaces of airway epithelial cells. TLR engagement leads to the initiation of a signaling cascade that results in a pro-inflammatory response with subsequent up-regulation of several cytokines and leads to adaptive immune responses. We examined the ability of two soluble flagellins, a monomeric flagellin expressed in Escherichia coli and a highly purified polymeric flagellin directly isolated from Salmonella, to enhance the efficacy of influenza vaccines in mice. Here we demonstrate that both flagellins co-administered intranasally with inactivated A/PR/8/34 (PR8) virus induced robust increases of systemic influenza-specific IgA and IgG titers and resulted in a more comprehensive humoral response as indicated by the increase of IgG2a and IgG2b subclass responses. Groups immunized with the adjuvanted vaccines were fully protected against high dose lethal challenge by homologous virus whereas inactivated PR8 alone conferred only partial protection. Finally we show that shortly after immunization the adjuvanted vaccines induced a dramatic increase in pro-inflammatory cytokines in the lung, resulting in extensive lung infiltration by granulocytes and monocytes/macrophages. Our results reveal a promising perspective for the use of both soluble monomeric and polymeric flagellin as mucosal vaccine adjuvants to improve protection against influenza epidemics as well as a range of other infectious diseases. (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19654062      PMCID: PMC3187848          DOI: 10.1016/j.vaccine.2009.07.058

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  58 in total

Review 1.  Innate immune induction of the adaptive immune response.

Authors:  R Medzhitov; C A Janeway
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1999

2.  The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5.

Authors:  F Hayashi; K D Smith; A Ozinsky; T R Hawn; E C Yi; D R Goodlett; J K Eng; S Akira; D M Underhill; A Aderem
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

3.  New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin.

Authors:  Daniel Y Bargieri; Daniela S Rosa; Catarina J M Braga; Bruna O Carvalho; Fabio T M Costa; Noeli Maria Espíndola; Adelaide José Vaz; Irene S Soares; Luis C S Ferreira; Mauricio M Rodrigues
Journal:  Vaccine       Date:  2008-09-18       Impact factor: 3.641

4.  Characterization of CD4+ T cell responses during natural infection with Salmonella typhimurium.

Authors:  S J McSorley; B T Cookson; M K Jenkins
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

5.  Salmonella typhimurium translocates flagellin across intestinal epithelia, inducing a proinflammatory response.

Authors:  A T Gewirtz; P O Simon; C K Schmitt; L J Taylor; C H Hagedorn; A D O'Brien; A S Neish; J L Madara
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

6.  Induction of CD4(+) T-cell-independent immunoglobulin responses by inactivated influenza virus.

Authors:  Z Sha; R W Compans
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

7.  Influenza virus vaccination induces interleukin-12/23 receptor beta 1 (IL-12/23R beta 1)-independent production of gamma interferon (IFN-gamma) and humoral immunity in patients with genetic deficiencies in IL-12/23R beta 1 or IFN-gamma receptor I.

Authors:  Tjitske de Boer; Jaap T van Dissel; Taco W J Kuijpers; Guus F Rimmelzwaan; Frank P Kroon; Tom H M Ottenhoff
Journal:  Clin Vaccine Immunol       Date:  2008-06-18

8.  Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates.

Authors:  Steven B Mizel; Aaron H Graff; Nammalwar Sriranganathan; Sean Ervin; Cynthia J Lees; Mark O Lively; Roy R Hantgan; Michael J Thomas; James Wood; Brian Bell
Journal:  Clin Vaccine Immunol       Date:  2008-11-05

9.  Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses.

Authors:  Bao-Zhong Wang; Fu-Shi Quan; Sang-Moo Kang; Jadranka Bozja; Ioanna Skountzou; Richard W Compans
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

10.  Ozone exposure of macrophages induces an alveolar epithelial chemokine response through IL-1alpha.

Authors:  Rizwan Manzer; Charles A Dinarello; Glen McConville; Robert J Mason
Journal:  Am J Respir Cell Mol Biol       Date:  2007-09-27       Impact factor: 6.914

View more
  48 in total

1.  Enhanced antigen processing of flagellin fusion proteins promotes the antigen-specific CD8+ T cell response independently of TLR5 and MyD88.

Authors:  John T Bates; Aaron H Graff; James P Phipps; Jason M Grayson; Steven B Mizel
Journal:  J Immunol       Date:  2011-04-22       Impact factor: 5.422

Review 2.  Dysregulation of human Toll-like receptor function in aging.

Authors:  Albert C Shaw; Alexander Panda; Samit R Joshi; Feng Qian; Heather G Allore; Ruth R Montgomery
Journal:  Ageing Res Rev       Date:  2010-11-10       Impact factor: 10.895

3.  Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand.

Authors:  Bao-Zhong Wang; Harvinder S Gill; Sang-Moo Kang; Li Wang; Ying-Chun Wang; Elena V Vassilieva; Richard W Compans
Journal:  Clin Vaccine Immunol       Date:  2012-05-30

4.  Flagellin-expressing virus-like particles exhibit adjuvant effects on promoting IgG isotype-switched long-lasting antibody induction and protection of influenza vaccines in CD4-deficient mice.

Authors:  Eun-Ju Ko; Youri Lee; Young-Tae Lee; Yu-Jin Jung; Vu L Ngo; Min-Chul Kim; Ki-Hye Kim; Bao-Zhong Wang; Andrew T Gewirtz; Sang-Moo Kang
Journal:  Vaccine       Date:  2019-05-14       Impact factor: 3.641

5.  A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors.

Authors:  Chunmei Cheng; Pooja Jain; Ilham Bettahi; Sukumar Pal; Delia Tifrea; Luis M de la Maza
Journal:  Vaccine       Date:  2011-07-08       Impact factor: 3.641

6.  Effect of C-Terminus Modification in Salmonella typhimurium FliC on Protein Purification Efficacy and Bioactivity.

Authors:  Mohammad-Hosein Khani; Masoumeh Bagheri; Ali Dehghanian; Azadeh Zahmatkesh; Soheila Moradi Bidhendi; Zahra Salehi Najafabadi; Reza Banihashemi
Journal:  Mol Biotechnol       Date:  2019-01       Impact factor: 2.695

7.  A method for the purification of bacterial flagellin that allows simple upscaling.

Authors:  Yanina Hiriart; Agustina Errea; Dolores González Maciel; Juan Carlos Lopez; Martin Rumbo
Journal:  World J Microbiol Biotechnol       Date:  2011-05-22       Impact factor: 3.312

8.  Different antigen presentation tendencies of granulocyte-macrophage colony-stimulating factor-induced bone marrow-derived macrophages and peritoneal macrophages.

Authors:  Maozhi Hu; Zhiming Pan; Yun Yang; Chuang Meng; Shizhong Geng; Meng You; Xinan Jiao
Journal:  In Vitro Cell Dev Biol Anim       Date:  2012-07-18       Impact factor: 2.416

9.  Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection.

Authors:  Bao-Zhong Wang; Rui Xu; Fu-Shi Quan; Sang-Moo Kang; Li Wang; Richard W Compans
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

10.  Mucosal adjuvants for influenza virus-like particle vaccine.

Authors:  Fu-Shi Quan; Eun-Ju Ko; Young-Man Kwon; Kyoung Hwan Joo; Richard W Compans; Sang-Moo Kang
Journal:  Viral Immunol       Date:  2013-11-16       Impact factor: 2.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.